Jennifer Choo Joins Menicon as Specialty Lens Clinical Manager
– Menicon Expanding Its Presence in Custom Contact Lens Market –
NAGOYA, japan, Aug. 23.- Menicon Company Ltd. announced on August 23 the appointment of Dr. Jennifer Choo as Manager of Specialty Lens Clinical Affairs for Menicon Holdings B.V. Dr. Choo will oversee the company's Rose K business while also handling professional and clinical affairs for the company's growing specialty lens portfolio.
For the last 3 years, Dr. Choo has been Project Leader at Adventus Technology Inc. and the Brien Holden Vision Institute (BHVI) based in Sydney, Australia. Dr. Choo has led and managed international and interdisciplinary teams in the development of innovative surgical ophthalmic products. She previously served as Project Director for Orthokeratology Research at BHVI while completing her PhD.
Dr. Choo completed a Bachelor of Science in Cell Biology and Genetics from the University of British Columbia in Vancouver. She obtained her Doctor of Optometry from the Pacific University College of Optometry in Portland, Oregon, and received her PhD in Vision Science from the University of New South Wales in Sydney, Australia.
Dr. Choo has strong global experience as a lecturer and educator and is a recipient of several research awards. She has also demonstrated outstanding leadership skills while overseeing the development, production and evaluation of novel ophthalmic devices. Dr. Choo will be based in Vancouver, Canada, and will report to Mr. Jonathan Jacobson, Chief Executive Officer of Menicon Holdings B.V.
"I am extremely excited to be joining the Menicon team," said Dr. Choo. "Menicon is a diverse, dynamic and multinational company that continually works to improve and innovate within the contact lens and lens care markets. I look forward to working with the team and utilizing my skills and experiences to help expand and establish the company's presence globally."
Mr. Jacobson commented: "We are thrilled to welcome Dr. Choo to Menicon. Her considerable experience in clinical research and specialty lenses will be invaluable to Menicon's global expansion plans, particularly during an active period of new product introductions."